Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Nanobiotechnology in Neurodegenerative Diseases

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F19%3A73596656" target="_blank" >RIV/61989592:15310/19:73596656 - isvavai.cz</a>

  • Výsledek na webu

    <a href="http://dx.doi.org/10.1007/978-3-030-30930-5_4" target="_blank" >http://dx.doi.org/10.1007/978-3-030-30930-5_4</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1007/978-3-030-30930-5_4" target="_blank" >10.1007/978-3-030-30930-5_4</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Nanobiotechnology in Neurodegenerative Diseases

  • Popis výsledku v původním jazyce

    “Neurodegenerative disease” is a term for a variety of disorders that primarily affect neurons in the human brain and spinal cord. These diseases are presently incurable and result in progressive degeneration or death of nerve cells, resulting in impaired movement (ataxia, Parkinsonism, paresis) or mental functions (dementia). The most common neurodegenerative diseases include Parkinson’s disease and other parkinsonian syndromes, Alzheimer’s disease and other non-Alzheimer’s dementias, Friedreich’s disease and other spinocerebellar atrophy, amyotrophic lateral sclerosis, and other diseases manifesting symptoms such as restriction of free movement, tremor, chorea, dystonia, myoclonus, other abnormal movements, dementia, and other cognitive disorders. Neurodegenerative diseases are highly prevalent and are among the most serious diseases in terms of health and socioeconomic impact. These diseases are not limited to older age groups, but affect also children and adults of working age. The current therapies cannot cure the diseases; they only ameliorate or relieve symptoms. All employed drugs have their targeted site of action in the central nervous system; thus, overcoming the blood–brain barrier is a necessity. Nanotechnology provides a new dimension and new properties to all materials and, in particular, allows central nervous system targeting of nanoscale formulations with increased brain permeation, and it is, thus, widely used for the production of a new generation of pharmaceuticals and theranostics with improved drug bioavailability, reduced undesirable side effects, minimized nonspecific uptake, and specific targeting to certain target cells. This chapter presents a comprehensive overview of recent findings in the field of investigation and application of nanoformulations tested/used for the alleviation or treatment of Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington’s disease, and Wilson’s disease as well as nanosensors applied for diagnostics or a treatment monitoring of neurodegenerative diseases.

  • Název v anglickém jazyce

    Nanobiotechnology in Neurodegenerative Diseases

  • Popis výsledku anglicky

    “Neurodegenerative disease” is a term for a variety of disorders that primarily affect neurons in the human brain and spinal cord. These diseases are presently incurable and result in progressive degeneration or death of nerve cells, resulting in impaired movement (ataxia, Parkinsonism, paresis) or mental functions (dementia). The most common neurodegenerative diseases include Parkinson’s disease and other parkinsonian syndromes, Alzheimer’s disease and other non-Alzheimer’s dementias, Friedreich’s disease and other spinocerebellar atrophy, amyotrophic lateral sclerosis, and other diseases manifesting symptoms such as restriction of free movement, tremor, chorea, dystonia, myoclonus, other abnormal movements, dementia, and other cognitive disorders. Neurodegenerative diseases are highly prevalent and are among the most serious diseases in terms of health and socioeconomic impact. These diseases are not limited to older age groups, but affect also children and adults of working age. The current therapies cannot cure the diseases; they only ameliorate or relieve symptoms. All employed drugs have their targeted site of action in the central nervous system; thus, overcoming the blood–brain barrier is a necessity. Nanotechnology provides a new dimension and new properties to all materials and, in particular, allows central nervous system targeting of nanoscale formulations with increased brain permeation, and it is, thus, widely used for the production of a new generation of pharmaceuticals and theranostics with improved drug bioavailability, reduced undesirable side effects, minimized nonspecific uptake, and specific targeting to certain target cells. This chapter presents a comprehensive overview of recent findings in the field of investigation and application of nanoformulations tested/used for the alleviation or treatment of Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington’s disease, and Wilson’s disease as well as nanosensors applied for diagnostics or a treatment monitoring of neurodegenerative diseases.

Klasifikace

  • Druh

    C - Kapitola v odborné knize

  • CEP obor

  • OECD FORD obor

    21001 - Nano-materials (production and properties)

Návaznosti výsledku

  • Projekt

    <a href="/cs/project/LO1305" target="_blank" >LO1305: Rozvoj centra pokročilých technologií a materiálů</a><br>

  • Návaznosti

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Ostatní

  • Rok uplatnění

    2019

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název knihy nebo sborníku

    Nanobiotechnology in Neurodegenerative Diseases

  • ISBN

    978-3-030-30929-9

  • Počet stran výsledku

    73

  • Strana od-do

    65-138

  • Počet stran knihy

    398

  • Název nakladatele

    Springer Nature Switzerland AG

  • Místo vydání

    Cham

  • Kód UT WoS kapitoly